title: [Reirradiation of recurrent glioblastoma].
abstract: Patients with glioblastoma are treated by radiotherapy in combination with temozolamid. Recurrent and progressive disease can be managed by several treatment options. Some series reported about reirradiation of brain tumors, but there are no randomised studies. Modern high precise radiation techniques can be an option for a save and effective treatment without systemic side effects. The published series show median survival rates from 6 to 12 months. Concomitant systemic therapies are evaluated in phase I/II studies. Indication for irradiation and decision of the technique and fractionation scheme have to be chosen individually. There is no curative intent for reirradiation, possible serious side effects and negative influence on life quality have to be omitted.
authors.affiliation: Abteilung für Radio-Onkologie-Strahlentherapie, Landeskrankenhaus Vöcklabruck, Vöcklabruck, Österreich. dietmar.seewald@gespag.at
authors.forename: Dietmar
authors.initials: D
authors.lastname: Seewald
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003952:Diagnostic Imaging; D019583:Dose Fractionation, Radiation; D005909:Glioblastoma / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D007091:Image Processing, Computer-Assisted; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D011788:Quality of Life; D011880:Radiotherapy Planning, Computer-Assisted; D019233:Retreatment; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents